HOME Top Market Reports Humanized Mouse Model Market by Type (Genetic, Cell-based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoiesis, Oncology, Immunology & Infectious diseases) & End User(Pharmaceutical & Biotech Companies, CRO)) - Global Forecast to 2021

Humanized Mouse Model Market by Type (Genetic, Cell-based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoiesis, Oncology, Immunology & Infectious diseases) & End User(Pharmaceutical & Biotech Companies, CRO)) - Global Forecast to 2021

By: marketsandmarkets.com
Publishing Date: January 2017
Report Code: BT 4938

 

  Speak to Analyst Enquiry Before Buying Webinar
purchase report
download pdf  request for customisation


The humanized mouse model market is projected to reach USD 116.0 Million by 2021 from USD 73.3 Million in 2016, growing at a CAGR of 9.6% during the forecast period. The growth of the overall market can be attributed to the continuous support for research activities in the form of investments and grants, surge in the number of research activities involving humanized mouse models, increased R&D activities by pharmaceutical and biotechnology companies, and growing consumption of personalized medicine. In the coming years, the market is expected to witness the highest growth rate in the Asia-Pacific region. The high growth in the region can be attributed to increasing investments from government and private sector in China’s life sciences sector, rising focus on personalized medicine in China, growth in the pharmaceutical industry in India, research in regenerative medicine in Japan, increase in animal research in Malaysia, ongoing biomedical research activities in Australia, growth in translational and biomedical research in Singapore, and rising pharmaceutical and biotechnology R&D activities in South Korea.

North America is expected to account for the largest share of the global humanized mouse model market. North America’s leadership in the market can be attributed to the availability of support for research, growing monoclonal antibody production, preclinical activities by CROs and pharmaceutical R&D activities in the U.S., growing stem cell research in Canada, and government support for development of protein drugs.

On the basis of type, the market is segmented into genetic and cell-based humanized mouse model. In 2016, the genetic segment is expected to command the largest share of the global market. The cell-based humanized mouse models segment is projected to grow at the highest CAGR during the forecast period. The cell-based humanized mouse models segment is further segmented into CD34, PBMC, and BLT humanized mouse model. In 2016, the CD34 segment is expected to command the largest share of the cell-based humanized mouse model market.

On the basis application, the market is segmented into oncology, immunology & infectious diseases, neuroscience, toxicology, hematopoiesis, and other applications (which include rare diseases, graft-versus-host diseases, cardiovascular diseases, and regenerative medicine). In 2016, the oncology segment is expected to command the largest share of the market.

On the basis of end user, the humanized mouse model market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. In 2016, the pharmaceutical & biotechnology companies segment is projected to command the largest share of the market. However, the academic & research institutions segment is expected to grow at the highest CAGR during the forecast period.

Key players in the global market include The Jackson Laboratory (U.S.), Taconic Biosciences, Inc. (U.S.), Harbour Antibodies BV (China), HuMurine Technologies, Inc. (U.S.), Vitalstar Biotechnology Co. Ltd. (China), Crown Bioscience, Inc. (U.S.), ingenious targeting laboratory (U.S.), Axenis S.A.S (France), TRANS GENIC, Inc. (Japan), genOway S.A. (France), and Horizon Discovery Group plc (U.K.).

Stakeholders of the Humanized Mouse Model Market 

  • Mouse Model and Service Companies
  • Government and Private Research Institutes
  • Manufacturers and Suppliers of Animal Care Products
  • Contract Research Organizations (CROs)
  • Academic & Research Institutes
  • Venture Capitalists
  • Medical Research Centers
  • Animal Care Associations
  • Public and Private Animal Health Agencies

To know about the assumptions considered for the study, download the pdf brochure

Scope of the Report:

This research report categorizes the global market into the following segments:

Humanized Mouse Model Market, by Type

  • Genetic Humanized Mouse Model
  • Cell-based Humanized Mouse Model
    • CD34
    • PBMC
    • BLT

Humanized Mouse Model Market, by Application

  • Oncology
  • Immunology and Infectious Diseases
  • Neuroscience
  • Toxicology
  • Hematopoiesis
  • Other Applications

Humanized Mouse Model Market, by End User

  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Academic & Research Institutes

Humanized Mouse Model Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization option is available for the report:

Portfolio Assessment

Product Matrix, which gives a detailed comparison of the product portfolios of the top three companies in the market.

Table of Contents

1 Introduction (Page No. - 16)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 20)
    2.1 Research Methodology
    2.2 Secondary and Primary Research Methodology
           2.2.1 Secondary Research
                    2.2.1.1 Key Data From Secondary Sources
           2.2.2 Primary Research
                    2.2.2.1 Key Data From Primary Sources
                    2.2.2.2 Key Insights From Primary Sources
                    2.2.2.3 Key Industry Insights
    2.3 Market Size Estimation Methodology
    2.4 Market Forecast Methodology
    2.5 Market Data Validation and Triangulation
    2.6 Assumptions for the Study

3 Executive Summary (Page No. - 30)
    3.1 Introduction
    3.2 Conclusion

4 Premium Insights (Page No. - 36)
    4.1 Humanized Mouse Model Market:  Overview
    4.2 Regional Analysis: Global Market, By End User
    4.3 Global Market, By Application, 2016 vs 2021
    4.4 Regional Snapshot: Global Market

5 Market Overview (Page No. - 39)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Surge in Research Activities Involving Humanized Mouse Models
                               5.2.1.1.1 Mouse Models for Immunodeficiency Disorders
                               5.2.1.1.2 Mouse Models for Cancer
                               5.2.1.1.3 Mouse Models for Rare Diseases
                    5.2.1.2 Growing Adoption of Personalized Medicine to Fuel the Demand for Personalized Mouse Models
                    5.2.1.3 Continuous Support in the Form of Investments and Grants From the Government and Private Sectors
                               5.2.1.3.1 Funding/Grants By the National Institutes of Health (NIH)
                               5.2.1.3.2 Funding/Grants Received From Other Government Bodies
                    5.2.1.4 Increase in R&D Activities Carried Out By Pharmaceutical and Biotechnology Companies
           5.2.2 Restraints
                    5.2.2.1 Regulations and Laws Formulated for Ethical Use of Animals
                               5.2.2.1.1 The Animal Welfare Act (AWA)
                               5.2.2.1.2 Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals
                    5.2.2.2 Increased Use of Rat Models
           5.2.3 Opportunities
                    5.2.3.1 Increased Production of Monoclonal Antibodies
           5.2.4 Challenges
                    5.2.4.1 Advances in Zebrafish Model Development
                    5.2.4.2 Alternatives to Animal Testing
                    5.2.4.3 Limitations of Humanized Mouse Models

6 Clinical Trials and Research Studies Assessment (Page No. - 49)
    6.1 Introduction
    6.2 Clinical Trials
    6.3 Research Studies

7 Humanized Mouse Model Market, By Type (Page No. - 56)
    7.1 Introduction
    7.2 Genetic Humanized Mouse Model
    7.3 Cell-Based Humanized Mouse Model
           7.3.1 CD34 Humanized Mouse Model (Hu-CD34)
           7.3.2 PBMC Humanized Mouse Model
           7.3.3 BLT Humanized Mouse Model

8 Humanized Mouse Model Market, By Application (Page No. - 66)
    8.1 Introduction
    8.2 Oncology
           8.2.1 Agreements/Collaborations to Strengthen Cancer Research
           8.2.2 Continuous Grants/Funds to Support Cancer Research Studies
    8.3 Immunology and Infectious Diseases
    8.4 Neurosciences
           8.4.1 Grants/Funds for Neurological Research
    8.5 Toxicology
    8.6 Hematopoiesis
    8.7 Other Applications
           8.7.1 Increasing Funding for Rare Disease Research

9 Humanized Mouse Model Market, By End User (Page No. - 78)
    9.1 Introduction
    9.2 Pharmaceutical and Biotechnology Companies
    9.3 Contract Research Organizations
    9.4 Academic and Research Institutions

10 Global Humanized Mouse Model Market, By Region (Page No. - 85)
     10.1 Introduction
     10.2 North America
             10.2.1 U.S.
                        10.2.1.1 Availability of Support for Research in the U.S.
                        10.2.1.2 Preclinical Activities By Cros and Pharmaceutical R&D
                        10.2.1.3 Conferences and Other Events Contributing to the Spread of Innovation and Awareness
                        10.2.1.4 Growing Monoclonal Antibody Production
                        10.2.1.5 Development of Biosimilars Boosting the Demand for Preclinical Services
             10.2.2 Canada
                        10.2.2.1 Growing Stem Cell Research in Canada
                        10.2.2.2 Government Support for Development of Protein Drugs
     10.3 Europe
             10.3.1 Launch of Pro-Test Deutschland in Germany
             10.3.2 Flourishing Biotechnology Industry in Germany
             10.3.3 Emphasis on Quality Research Results in the U.K.
             10.3.4 Increase in Cell Therapy Preclinical Research in the U.K.
             10.3.5 Funding for Rare Disease Projects in France
             10.3.6 Growth in Italy’s Biotech and Pharma Sector
             10.3.7 Growing Investments in Research By Sweden and Denmark
     10.4 Asia-Pacific
             10.4.1 Strong Research Expenditure and Well-Structured Cro Industry in China
             10.4.2 Mandatory Animal Testing for All Pharmaceutical Drugs and Cosmetics in China
             10.4.3 Rising Focus on Personalized Medicine in China
             10.4.4 Increasing Investments From Government and Private Sectors in China’s Life Sciences Sector
             10.4.5 Government Support for Research, and Growth of Biomedical and Medical Research in Japan
             10.4.6 Research in Regenerative Medicine in Japan
             10.4.7 Growth of the Pharmaceutical Industry in India
             10.4.8 Development of Bio-Clusters to Boost India’s Biotechnology Sector
             10.4.9 Infrastructural Limitations in India: A Key Hindrance for Market Growth
             10.4.10 Ongoing Biomedical Research Activities in Australia
             10.4.11 Growth in Translational and Biomedical Research in Singapore
             10.4.12 Increase in Animal Research in Malaysia
             10.4.13 Rising Pharmaceutical and Biotechnology R&D Activities in Korea
     10.5 Rest of the World
             10.5.1 Growth in the Pharmaceutical, Biotechnology, and Research Industries in Brazil
             10.5.2 Favorable Business Environment for Pharmaceutical and Biotechnology Industries in Saudi Arabia and the UAE
             10.5.3 Increasing Investments in Mexico

11 Competitive Landscape (Page No. - 119)
     11.1 Overview
     11.2 Market Share Analysis
             11.2.1 Introduction
             11.2.2 Cell-Based Humanized Mouse Model Market
                        11.2.2.1 The Jackson Laboratory (U.S.)
                        11.2.2.2 Taconic Biosciences, Inc. (U.S.)
             11.2.3 Genetic Humanized Mouse Model Market
                        11.2.3.1 Horizon Discovery Group PLC (U.K.)
                        11.2.3.2 Taconic Biosciences, Inc. (U.S.)
     11.3 Competitive Situation and Trends
     11.4 Agreements, Collaborations, Contracts, Alliances, and Partnerships
     11.5 Grant/Fund
     11.6 Product Launches
     11.7 Expansions
     11.8 Acquisitions
     11.9 Other Strategies

12 Company Profiles (Page No. - 132)
(Overview, Products and Services, Financials, Strategy & Development)*
     12.1 Introduction
     12.2 The Jackson Laboratory
     12.3 Taconic Biosciences, Inc.
     12.4 Horizon Discovery Group PLC
     12.5 Genoway S.A.
     12.6 Harbour Antibodies Bv (A Subsidiary of Harbour Biomed)
     12.7 Humurine Technologies
     12.8 Vitalstar Biotechnology Co., Ltd.
     12.9 Ingenious Targeting Laboratory
     12.10 Axenis S.A.S
     12.11 Trans Genic, Inc.
     12.12 Champions Oncology, Inc.
     12.13 Crown Bioscience, Inc.

*Details on Overview, Products and Services, Financials, Strategy & Development Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. - 162)
     13.1 Discussion Guide
     13.2 Other Developments (2013–2016)
             13.2.1 The Jackson Laboratory
             13.2.2 Taconic Biosciences, Inc.
             13.2.3 Horizon Discovery Group PLC
             13.2.4 Genoway S.A.
             13.2.5 Ingenious Targeting Laboratory
             13.2.6 Trans Genic, Inc.
             13.2.7 Champions Oncology, Inc.
             13.2.8 Crown Bioscience, Inc.
     13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
     13.4 Introducing RT: Real-Time Market Intelligence
     13.5 Available Customizations
     13.6 Related Reports
     13.7 Author Details


List of Tables (69 Tables)
 
Table 1 Indicative List of Ongoing Clinical Trials Conducted on Humanized Mouse Models
Table 2 Indicative List of Research Studies Conducted on Humanized Mouse Models (2013–2016)
Table 3 Global Humanized Mouse Model Market Size, By Type, 2014–2021 (USD Million)
Table 4 Genetic Market Size, By Region, 2014–2021 (USD Million)
Table 5 Global Cell-Based Market Size, By Type, 2014–2021 (USD Million)
Table 6 Cell-Based Market Size, By Region, 2014–2021 (USD Million)
Table 7 North America: Cell-Based Humanized Mouse Model Market Size, By Country, 2014–2021 (USD Million)
Table 8 CD34 Market Size, By Region, 2014–2021 (USD Million)
Table 9 North America: CD34 Market Size, By Country, 2014–2021 (USD Million)
Table 10 PBMC Humanized Mouse Model Market Size, By Region, 2014–2021 (USD Million)
Table 11 North America: PBMC Market Size, By Country, 2014–2021 (USD Million)
Table 12 Recent Hiv Studies Using Humanized Mouse Model
Table 13 BLT Market Size, By Region, 2014–2021 (USD Thousand)
Table 14 North America: BLT Humanized Mouse Model Market Size, By Country, 2014–2021 (USD Thousand)
Table 15 Global Market, By Application, 2014–2021 (USD Million)
Table 16 Indicative List of Recent Cancer Research Studies Using Humanized Mouse Models
Table 17 Market for Oncology, By Region, 2014–2021 (USD Million)
Table 18 North America: Market Size for Oncology, By Country, 2014–2021 (USD Million)
Table 19 Humanized Mouse Model Market Size for Immunology and Infectious Diseases, By Region, 2014–2021 (USD Million)
Table 20 North America: Market Size for Immunology and Infectious Diseases, By Country, 2014–2021 (USD Million)
Table 21 Market Size for Neurosciences, By Region, 2014-2021 (USD Million)
Table 22 North America: Market Size for Neurosciences, By Country, 2014–2021 (USD Million)
Table 23 Humanized Mouse Model Market Size for Toxicology, By Region, 2014-2021 (USD Million)
Table 24 North America: Market Size for Toxicology, By Country, 2014–2021 (USD Million)
Table 25 Market Size for Hematopoiesis, By Region, 2014-2021 (USD Million)
Table 26 North America: Market Size for Hematopoiesis, By Country, 2014–2021 (USD Million)
Table 27 Humanized Mouse Model Market Size for Other Applications, By Region, 2014-2021 (USD Million)
Table 28 North America: Market Size for Other Applications, By Country, 2014–2021 (USD Million)
Table 29 Global Market, By End User, 2014–2021 (USD Million)
Table 30 Market Size for Pharmaceutical and Biotechnology Companies, By Region, 2014–2021 (USD Million)
Table 31 North America: Humanized Mouse Model Market Size for Pharmaceutical and Biotechnology Companies, By Country, 2014–2021 (USD Million)
Table 32 Market Size for Contract Research Organizations, By Region, 2014–2021 (USD Million)
Table 33 North America: Humanized Mouse Model Market Size for Contract Research Organizations, By Country, 2014–2021 (USD Million)
Table 34 Market Size for Academic and Research Institutions, By Region, 2014–2021 (USD Million)
Table 35 North America: Humanized Mouse Model Market Size for Academic and Research Institutions, By Country, 2014–2021 (USD Million)
Table 36 Market, By Region, 2014–2021 (USD Million)
Table 37 North America: Humanized Mouse Model Market, By Country, 2014–2021 (USD Million)
Table 38 North America: Market, By Type, 2014–2021 (USD Million)
Table 39 North America: Cell-Based Market Size, By Type, 2014–2021 (USD Million)
Table 40 North America: Humanized Mouse Model Market, By Application, 2014–2021 (USD Million)
Table 41 North America: Market, By End User, 2014–2021 (USD Million)
Table 42 NIH Funding for Projects Related to Animal Models
Table 43 Recent Events Related to the Animal Model Market
Table 44 U.S.: Humanized Mouse Model Market, By Type, 2014–2021 (USD Million)
Table 45 U.S.: Cell-Based Market Size, By Type, 2014–2021 (USD Million)
Table 46 U.S.: Market, By Application, 2014–2021 (USD Million)
Table 47 U.S.: Market, By End User, 2014–2021 (USD Million)
Table 48 Canada: Humanized Mouse Model Market, By Type, 2014–2021 (USD Million)
Table 49 Canada: Cell-Based Market Size, By Type, 2014–2021 (USD Thousand)
Table 50 Canada: Market, By Application, 2014–2021 (USD Thousand)
Table 51 Canada: Market, By End User, 2014–2021 (USD Million)
Table 52 Europe: Humanized Mouse Model Market, By Type, 2014–2021 (USD Million)
Table 53 Europe: Cell-Based Market Size, By Type, 2014–2021 (USD Million)
Table 54 Europe: Market, By Application, 2014–2021 (USD Million)
Table 55 Europe: Market, By End User, 2014–2021 (USD Million)
Table 56 Asia-Pacific: Humanized Mouse Model Market, By Type, 2014–2021 (USD Million)
Table 57 Asia-Pacific: Cell-Based Market Size, By Type, 2014–2021 (USD Thousand)
Table 58 Asia-Pacific: Humanized Mouse Model Market, By Application, 2014–2021 (USD Thousand)
Table 59 Asia-Pacific: Market, By End User, 2014–2021 (USD Million)
Table 60 RoW: Humanized Mouse Model Market, By Type, 2014–2021 (USD Million)
Table 61 RoW: Cell-Based Market Size, By Type, 2014–2021 (USD Thousand)
Table 62 RoW: Humanized Mouse Model Market, By Application, 2014–2021 (USD Thousand)
Table 63 RoW: Market, By End User, 2014–2021 (USD Million)
Table 64 Agreements, Collaborations, Contracts, Alliances, and Partnerships, 2013–2016
Table 65 Grant/Fund, 2013–2016
Table 66 Product Launches, 2013–2016
Table 67 Expansions, 2013–2016
Table 68 Acquisitions, 2013–2016
Table 69 Other Strategies, 2013–2016


List of Figures (47 Figures)
 
Figure 1 Global Humanized Mouse Model Market: Research Methodology
Figure 2 Sampling Frame: Primary Research
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Market Size Estimation Methodology: Bottom-Up Approach
Figure 5 Market Size Estimation Methodology: Top-Down Approach
Figure 6 Research Design
Figure 7 Data Triangulation Methodology
Figure 8 Global Market, By Application (2016)
Figure 9 Global Market, By Type
Figure 10 Global Cell-Based Market, By Type
Figure 11 Global Market, By End User
Figure 12 Asia-Pacific to Witness Highest Growth During the Forecast Period
Figure 13 Increasing R&D Activities, Investments, and Grants to Drive Growth in the Global Market
Figure 14 North America to Dominate the Global Humanized Mouse Model Market in 2016
Figure 15 Oncology to Form the Largest Application Segment in the Global Market
Figure 16 Asia-Pacific to Register the Highest Market Growth From 2016 to 2021
Figure 17 Drivers, Restraints, Opportunities, and Challenges
Figure 18 U.S.: Clinical Trials Using Humanized Mouse Models, By Indication (2013–2023)
Figure 19 U.S.: Clinical Trials Using Humanized Mouse Models, By Completion
Figure 20 U.S.: Clinical Trials Using Humanized Mouse Models, By Phase (2013–2023)
Figure 21 U.S.: Research Studies Using Humanized Mouse Models, By Indication (2012–2016)
Figure 22 Genetic Humanized Mouse Model to Account for the Largest Market Share in 2016
Figure 23 CD34 Humanized Mouse Model to Grow at the Highest CAGR Between 2016 and 2021
Figure 24 Oncology Segment to Dominate the Humanized Mouse Model Market in 2016
Figure 25 Pharmaceutical and Biotechnology Companies to Dominate the Market in 2016
Figure 26 North America Dominates the Market for Humanized Mouse Models
Figure 27 North America: Humanized Mouse Model Market Snapshot
Figure 28 Europe: Market Snapshot
Figure 29 Increase in Cell Therapy Preclinical Studies in the U.K., 2013-2016
Figure 30 Asia-Pacific: Market Snapshot
Figure 31 Rest of the World: Market Snapshot
Figure 32 Key Developments in the Market, 2013–2016
Figure 33 Market Share Analysis for Cell-Based Humanized Mouse Model, By Key Player, 2015
Figure 34 Market Share Analysis for Genetic Humanized Mouse Model, By Key Player, 2015
Figure 35 Agreements, Collaborations, Contracts, Alliances, and Partnerships Was the Key Growth Strategy Adopted By Market Players
Figure 36 Agreements, Collaborations, Alliances, Contracts, and Partnerships, By Company (2013–2016)
Figure 37 Grant/Fund, By Company (2013–2016)
Figure 38 Product Launches, By Company (2013–2016)
Figure 39 Expansions, By Company (2013–2016)
Figure 40 Acquisitions, By Company (2013–2016)
Figure 41 Other Strategies, By Company (2013–2016)
Figure 42 Product Mix of the Top 3 Players in the Humanized Mouse Models Market
Figure 43 The Jackson Laboratory: Company Snapshot (2015)
Figure 44 Horizon Discovery Group PLC: Company Snapshot (2015)
Figure 45 Genoway S.A.: Company Snapshot (2015)
Figure 46 Trans Genic, Inc.: Company Snapshot (2015)
Figure 47 Champions Oncology, Inc.: Company Snapshot (2015)

The humanized mouse model market is projected to reach USD 116.0 Million by 2021 from 73.3 Million in 2016, growing at a CAGR of 9.6% during the forecast period. The growth of the overall market can be contributed to surge in the number of research activities involving humanized mouse models, increased R&D activities by pharmaceutical and biotechnology companies, and growing adoption of personalized medicine. In addition to this, continuous support for research activities in the form of investments and grants is further stimulating the market growth.

The global market is categorized on the basis of type, application, end user, and region. On the basis of type, the market is categorized into genetic and cell-based humanized mouse model. The genetic segment is estimated to account the largest share of the global market, by type. The cell-based humanized mouse model segment is further divided into CD34, PBMC, and BLT humanized mouse model. In 2016, the CD34 segment is expected to command the largest share of the cell-based humanized mouse model market. CD34 mice models are used as in vivo platforms for analyzing the safety and effectiveness of potential new drugs that can modulate the immune system. Additionally, they are used for long-term studies in the fields of immuno-oncology, infectious disease, and graft versus host disease. Thus, the growing application areas of CD34 models are expected to trigger the demand for these models in the coming years.

On the basis of application, the global market is segmented into oncology, immunology and inflammation, neuroscience, hematopoiesis, toxicology, and other applications. The oncology segment is estimated to command the largest share of the global market in 2016. This segment is projected to grow at the highest CAGR during the forecast period. The growth of this segment can be attributed to increasing research activities and growing funding from various governments to carry out research studies on cancer.

On the basis of end user, the market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. In 2016, the pharmaceutical & biotechnology companies segment is expected to command the largest share of the market.

North America is expected to account for the largest share of the global market. The large share of this segment can be attributed to rising biomedical research and increased R&D spending by pharmaceutical companies. In the coming years, the humanized mouse model market is expected to witness the highest growth rate in the Asia-Pacific region. The high growth in the region can be attributed to rising focus on personalized medicine in China, increasing investments from government and private sector in China’s life sciences sector, research in regenerative medicine in Japan, increase in animal research in Malaysia, growth in the pharmaceutical industry in India, growth in translational and biomedical research in Singapore, and rising pharmaceutical and biotechnology R&D activities in South Korea.

Humanized Mouse Model Market

Key players in the global humanized mouse model market include The Jackson Laboratory (U.S.), Taconic Biosciences, Inc. (U.S.), Harbour Antibodies BV (China), HuMurine Technologies, Inc. (U.S.), Vitalstar Biotechnology Co. Ltd. (China), Crown Bioscience, Inc. (U.S.), ingenious targeting laboratory (U.S.), Axenis S.A.S (France), TRANS GENIC, Inc. (Japan), genOway S.A. (France), and Horizon Discovery Group plc (U.K.).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports



Access reports on all high
growth Biotechnology Markets on KnowledgeStore
Request Demo